LifeTech Scientific Corporation
先健科技公司

(Incorporated in the Cayman Islands with limited liability)
(Stock code: 1302)

VOLUNTARY ANNOUNCEMENT

Publication of the Two-Year Follow-Up Results of Phase II Clinical Study and Phase III Clinical Study of IBS® Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System

This announcement is made by LifeTech Scientific Corporation (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to provide its shareholders and potential investors with information in relation to the latest business and new product development of the Group.

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that the two-year follow-up of the phase II clinical study (the "**Phase II Clinical Study**") and phase III clinical study (the "**Phase III Clinical Study**") on the Group's self-developed IBS® Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System ("**IBS® Coronary Scaffold**" or the "**Product**") has been successfully completed, and the two-year primary endpoint angiography follow-up results of Phase II Clinical Study and the two-year clinical endpoint follow-up results of Phase III Clinical Study of IBS® Coronary Scaffold were announced globally by Dr. Lei Song (宋雷), the professor of Fuwai Hospital, Chinese Academy of Medical Sciences, on behalf of Academician Runlin Gao (高潤霖) and the entire clinical research team, at the Transcatheter Cardiovascular Therapeutics 2025 (the "**TCT 2025**") on 26 and 27 October 2025 local time in the United States.

The Phase II Clinical Study on IBS® Coronary Scaffold is a prospective, multi-center, single-blinded, randomized clinical trial. The primary endpoint of the study was in-segment late lumen loss two years after the implantation of the coronary scaffold. The Phase II Clinical Study was enrolled in March 2022 and 518 subjects were successfully enrolled within nine months in 36 domestic study sites, with a 1:1 random allocation to the experimental group (IBS® Coronary Scaffold) and the

control group (Xience® Everolimus Eluting Coronary Stent). The two-year follow-up results showed that the in-segment late lumen loss (experimental group: 0.28 ± 0.52 mm, control group : 0.23 ± 0.43 mm), the primary endpoint has achieved non-inferiority. There was no experimental stent thrombosis in the experimental group, but one occurred in the control group.

The Phase III Clinical Study on IBS® Coronary Scaffold is a prospective, multi-center, single-arm clinical trial. The primary endpoint of the study was the Target Lesion Failure ("**TLF**") one year after the implantation of IBS® Coronary Scaffold, and the Phase III Clinical Study was enrolled in February 2023. A total of 1,060 patients were enrolled for the Phase III Clinical Study, including more than 200 subjects whom implanted IBS® Coronary Scaffold in the Phase II Clinical Study and over 800 subjects enrolled additionally for Phase III Clinical Study. Two years after implantation, clinical follow-up was completed in 1,051 cases, with a follow-up rate of 99%. The two-year clinical follow-up results showed that two years after the implantation of IBS® Coronary Scaffold, the TLF was 5.5%. Only five cases of experimental stent thrombosis occurred in the trial over two years, and the incidence of thrombotic events was 0.5% only. Four of these cases occurred within a month, while three of which were clearly non-device related.

IBS® Coronary Scaffold is the world's first iron-based bioresorbable coronary scaffold, as far as the Company is aware. The backbone is processed from high-purity nitrided iron tubes with high strength and plasticity, and the strut is thin with a high radial strength. The innovative material research and unique technological approach enable the Product to retain the advantages of permanent metal coronary stents, namely complete specifications, superior physical properties, good biocompatibility, simple operation, and make it fully absorbable, thereby effectively avoiding a series of long-term prognosis issues that may arise from the implantation of permanent metal stents.

Compared with other bioresorbable scaffolds (TLF 1.7-11.2%) and permanent metal stents (TLF 3.0-11.9%) on the market, the two-year follow-up results of IBS® Coronary Scaffold are at an ideal level. Combining the post-hoc analysis of the full samples of the Phase II Clinical Study and Phase III Clinical Study, the TLF of the Product has also achieved non-inferiority during the two-year follow-up. As a global innovative product, IBS® Coronary Scaffold received high praise from cardiovascular experts at TCT 2025. This study, which enrolled comparatively challenging patients among all clinical studies of bioresorbable scaffold in China and abroad, achieved excellent results. It demonstrates that the IBS® Coronary Scaffold is not inferior to the current mainstream drug-eluting metal stent on the market, validating the medium and long term safety and effectiveness of the iron-based biodegradable coronary scaffold in over 1,000 cases.

The announcement of the two-year follow-up results of the Phase II Clinical Study and Phase III Clinical Study of IBS® Coronary Scaffold further enhances the evidence-based medical evidences for this innovative product. Currently, the follow-up data from the IBS® Coronary Scaffold clinical study has been submitted to the National Medical Products Administration ("**NMPA**") and the European Union for CE registration approval. It is expected that IBS® Coronary Scaffold will offer an unprecedented, safe and effective treatment for patients with coronary heart disease all over the world, and lay a solid foundation for the global development of other core products on the iron-based bioresorbable material platform of the Company.

By order of the Board
LifeTech Scientific Corporation
XIE Yuehui
Executive Director, Chairman and Chief Executive Officer

Hong Kong, 29 October 2025

As at the date of this announcement, the Board comprises Mr. XIE Yuehui, Mr. LIU Jianxiong and Ms. RUAN Xingmei being executive Directors; Mr. JIANG Feng being non-executive Director; and Mr. LIANG Hsien Tse Joseph, Mr. WANG Wansong and Mr. ZHOU Luming being independent non-executive Directors.